SCIENTIFIC PROGRAM

Wednesday September 25

8:30 – 8:40 Opening Remark
Shuichi Ikeda (Chairperson)

8:40 – 8:50 Message to Participants
Fumimaro Takaku (Japan Intractable Disease Research Foundation)

I. Basic Science

8:50 – 10:00 a) Biology of TTR and Amyloidogenesis
Chair: Jeffery W. Kelly (La Jolla, U.S.A.)
Shuichiro Maeda (Yamanashi, Japan)

Keynote Lectures

8:50 I-a-1 Pathogenesis of Transthyretin Amyloidosis
Merrill D. Benson
Indianapolis, U.S.A.

9:10 I-a-2 Transthyretin in Health and Amyloid Disease
Maria João M. Saraiva
Porto, Portugal

9:30 I-a-3 Microheterogeneity of Human Plasma Transthyretin
Klaus Altland
Giessen, Germany

Oral Presentation

9:50 I-a-4 Transthyretin Amyloidogenesis: Clues from Protein Stability and Folding
Alexandre Quintas, Daniel C. Vaz, Maria João M. Saraiva, Rui M. M. Brito
Coimbra, Portugal

10:00 – 11:00 Poster Discussion (I-P-1～II-P-25) and Coffee Break

11:00 – 12:00 b) Animal Models
Chair: Maria João M. Saraiva (Porto, Portugal)
Takahiko Tokuda (Matsumoto, Japan)

Keynote Lectures

11:00 I-b-1 Study on the Molecular Basis of Familial Amyloidotic Polyneuropathy by the Use of Genetically Altered Mice
Shuichiro Maeda
Yamanashi, Japan
11:20  I-b-2  Mouse ApoA-II Amyloidosis: Genetics, Epigenetics and Transmission  
Keiichi Higuchi  
Matsumoto, Japan

Oral Presentations
11:40  I-b-3  Of Mice and Men: The Case of Differential Regulation of the TTR Gene  
Ludmila Prokunina, Martina Gaspari, Christina Thylén  
Stockholm, Sweden
11:50  I-b-4  Evidence for Early Cytotoxic Aggregates in Transgenic Mice for Transthyretin Leu55Pro  
Mónica Mendes Sousa, Rui Fernandes, João Almeida Patra, Ana Taboada, Paulo Vieira, Maria João M. Saravia  
Porto, Portugal

12:00 — 13:30  Lunch Break

13:30 — 14:20  c) Mechanisms Leading to Nerve Degeneration  
Chair: Reinhold P. Linke (Martinsried, Germany)  
Gen Sobue (Nagoya, Japan)

Keynote Lectures
13:30  I-c-1  Familial Amyloid Polyneuropathy: Mechanisms Leading to Nerve Degeneration  
Gérard Saïd  
Le Kremlin Bicêtre, France
13:50  I-c-2  Pathomechanisms of Neuromuscular Disorders in AL and TTR Amyloidoses  
Masahito Yamada  
Kanazawa, Japan

Oral Presentation
14:10  I-c-3  Assessment of Morphological and Functional Changes in the Skin Venules in FAP Patients with Near-infrared Spectrophotoscopy Technique  
Kozen Ohbayashi, Yukio Ando, Masaaki Nakamura, Taro Yamashita, Katsuki Haraoka, Mitsuharu Ueda, Makoto Uchino  
Kumamoto, Japan

14:20 — 16:00  Poster discussion (II-P-26 ~ II-P-55) and Coffee break
16:00—17:00  d) Senile Transthyretin Amyloidosis

Chair: Gösta Holmgren (Umeå, Sweden)
Keiichi Higuchi (Matsumoto, Japan)

Keynote Lectures
16:00  1-d-1  Transthyretin-Derived Senile Systemic Amyloidosis: Homogeneity and Heterogeneity
        Per Westermark
        Uppsala, Sweden
16:20  1-d-2  The Pathogenesis of Transthyretin Tissue Deposition: Lessons from Transgenic Mice
        Joel N. Buschbaum
        La Jolla, U.S.A.

Oral Presentations
16:40  1-d-3  Senile Cardiac Amyloidosis: Serum Levels of S-sulfated Transthyretin (TTR)
        L.H. Connors, J. Karbasri, A. Lim, C.E. Costello, M. Skinner
        Boston, U.S.A.
16:50  1-d-4  Contribution of Normal Transthyretin to Cardiac Amyloidosis after Liver Transplantation
        Juris J. Liepmens, Masahide Yazaki, Merrill D. Benson
        Indianapolis, U.S.A.

17:30— Party in the Garden of Matsumoto Castle
II. Clinical Problems

8:30 — 10:00  e) Clinicopathological heterogeneity

Chair: Fabrizio Salvi (Bologna, Italy)
Maria de Lurdes Sales Luis (Lisbon, Portugal)

Keynote Lectures

8:30  II-e-1  Clinicopathologic and Genetic Features of Late- and Early-Onset FAP Type I (FAP TTR Val30Met) in Japan
Gen Sobue
Nagoya, Japan

8:50  II-e-2  Clinicopathological heterogeneity of non-Val30Met TTR type FAP in Japan
Shu-ichi Ikeda
Matsumoto, Japan

9:10  II-e-3  Hereditary Gelsolin-Related FAP
Sari Kiusu-Enari
Helsinki, Finland

Oral Presentations

9:30  II-e-4  Clinical Variability in Familial Amyloidotic Polyneuropathy Type I (Val30Met) — Comparison Between Late and Early Age-of-Onset
I Conceição M. de Carvalho
Lisbon, Portugal

9:40  II-e-5  Fibrillogenesis in Gelsolin-Related Amyloidosis
C. P. J. Maury, E-L. Nurmiaho-Lassila, M. Lijstom
Helsinki, Finland

9:50  II-e-6  Clinical Picture of Gelsolin-Related FAP in Japan
Yoshitake Sumiida
Kurashiki, Japan

10:00 — 11:00  f) Presymptomatic Gene Testing and Genetic Counseling

Chair: Merrill D. Benson (Indianapolis, U.S.A.)
Masahito Yamada (Kanazawa, Japan)

Keynote Lectures

10:00  II-f-1  Presymptomatic Gene Testing and Genetic Counseling in Familial Amyloid Polyneuropathy (FAP). Genetic Information to the Individuals in Japanese FAP Families
Shu-ichi Ikeda
Matsumoto, Japan

10:20  II-f-2  Special Considerations at Presymptomatic Gene Testing and Genetic Counseling in the Swedish FAP Population — High Gene Carrier Frequency and Low Penetrance
Gosta Holmgren
Umea, Sweden
10:40  II-f-3  Clinical and Therapeutical Implications of Presymptomatic Gene Testing for FAP
Maria de Lurdes Sales Lúis
Lisbon, Portugal

11:00 — 11:30  Coffee Break

11:30 — 12:10  g) New Approaches to Treatment
Chair: Gösta Holmgren (Umeå, Sweden)
C. P. J. Maury (Helsinki, Finland)

Keynote Lectures
11:30  II-g-1  Understanding the Energy Landscapes Associated with Transthyretin Amyloid Diseases and Manipulating Them to Prevent Amyloidosis.
Jeffery W. Kelly
La Jolla, U.S.A.

11:50  II-g-2  New Therapeutic Approaches for Familial Amyloidotic Polyneuropathy (FAP)
Yukio Ando
Kumamoto, Japan

12:30 —  Excursion to Kurobe Canyon

18:00 —  Congress Dinner at Kuroyon Royal Hotel
Friday September 27

III. Liver Transplantation

8:30—9:20  h) 10-Year-Experience for FAP
Chair: Ole B. Suhr (Umeå, Sweden)
Yukihiro Inomata (Kumamoto, Japan)

Keynote Lectures
8:30  III-h-1  10-Year Experience with FAP. Report from The FAP World Transplant Registry
Bo-Göran Ericzon
Stockholm, Sweden

8:50  III-h-2  Living Related Liver Transplantation (LRLT) for FAP
Setji Kawasaki
Matsumoto, Japan

Oral Presentation
9:10  III-h-3  Long Term Effect of Liver Transplantation (LT) on Met 30 TTR Familial Amyloid Polyneuropathy (FAP)
David Adams, Didier Samuel, Anne Kreib, Violaine Plante, Henri Bismuth, Gerard Saïd
Paris, France

9:20—10:30  Poster Discussion (III-P-56~III-P-73) and Coffee Break

10:30—11:20  i) Complications after Transplantation
Chair: Alexandre Jose Linhares L. Furtado (Coimbra, Portugal)
Didier Samuel (Villejuif, France)

Keynote Lectures
10:30  III-i-1  Impact of Liver Transplantation on FAP Symptoms and Complications
Ole B. Suhr
Umeå, Sweden

10:50  III-i-2  Challenges in the Early Management of FAP Patients after Liver Transplantation
Stephen V. Lynch
Brisbane, Australia

Oral Presentation
11:10  III-i-3  Long-Term Impact of Liver Transplantation on Familial Amyloidotic Polyneuropathy Patients' Kidney Function
Grzegorz Nowak, Ole B. Suhr, Lars Wikström, Henryk Wilczek, Bo-Göran Ericzon
Stockholm, Sweden

11:20—12:30  Lunch Break
12:30 — 13:10  j) Indication and Prognosis for non-Val30Met TTR Type FAP
Chair: Bo-Göran Ericzon (Stockholm, Sweden)
Seiji Kawasaki (Matsumoto, Japan)

Keynote Lectures
12:30  III-j-1  Cardiac Amyloid in Patients with Familial Amyloid Polyneuropathy Consists of Abundant Wild-Type Transthyretin
Takahiko Tokuda
Matsumoto, Japan

12:50  III-j-2  Isolated Liver Transplant (OLT) or Combined Liver/Kidney Transplant for End Stage Hepatic Amyloid due to AL or due to Hereditary Amyloidosis
Arie J. Stengou
London, U.K.

13:10 — 13:50  k) Domino Transplantation
Chair: Bo-Göran Ericzon (Stockholm, Sweden)
Seiji Kawasaki (Matsumoto, Japan)

Keynote Lectures
13:10  III-k-1  Domino Liver Transplantation Using FAP Grafts — HUC Experience: Hopes and Realities
A. J. Linhares Furtado
Lisbon, Portugal

13:30  III-k-2  Domino Liver Transplantation: A French Experience
Didier Samuel
Villejuif, France

13:50 — 14:00  IV. Summary of This Symposium
Joel N. Buxbaum
La Jolla, U.S.A.

14:00 — 14:05  Closing Remark
Shu-ichi Ikeda (Chairperson)
## POSTER DISCUSSION

**Wednesday September 25 (10:00 —11:00)**

<table>
<thead>
<tr>
<th>I-P-01</th>
<th>Detection of amyloid in vivo using BSB</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Yutaka Tanoue, Yukio Ando, Katsuki Haraoka, Kazuko Nakagawa, Takashi Ishizaki</td>
</tr>
<tr>
<td></td>
<td>Kumamoto, Japan</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>I-P-02</th>
<th>Binding of wild type and variant TTR to PCB and its metabolites</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Takahiro Tajiri, Yukio Ando, Yutaka Tanoue, Kazuko Nakagawa, Takashi Ishizaki</td>
</tr>
<tr>
<td></td>
<td>Kumamoto, Japan</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>I-P-03</th>
<th>Role of lipoprotein in amyloid formation in FAP</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Yuguo Sun, Yukio Ando, and Hiroaki Okabe</td>
</tr>
<tr>
<td></td>
<td>Kumamoto, Japan</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>I-P-04</th>
<th>Transthyretin amyloidogenesis altered by Cr³⁺ and Al³⁺</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Fumi Mikami, Yukio Ando, Akira Inasato, Takahiro Tajiri, Takashi Sato, Tsuyoshi Shuto, Hirofumi Kai</td>
</tr>
<tr>
<td></td>
<td>Kumamoto, Japan</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>I-P-05</th>
<th>Analysis of autoantibody against the variant transthyretin (TTR) in sera of sequential liver transplantation patients using explanted livers</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>H. Terazaki, Yukio Ando, M.J.M. Saraiva</td>
</tr>
<tr>
<td></td>
<td>Kumamoto, Japan</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>I-P-06</th>
<th>Detection of transthyretin aggregates in FAP human samples and transgenic mice using a retention filter assay</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>H. Terazaki, I. Cardoso, M.J.M. Saraiva</td>
</tr>
<tr>
<td></td>
<td>Kumamoto, Japan</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>I-P-07</th>
<th>FAP ATTR Val30Met with extracellular superoxide dismutase (EC-SOD) mutation</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Mitsuharu Ueda, Yukio Ando, Masaaki Nakamura, and Makoto Uchino</td>
</tr>
<tr>
<td></td>
<td>Kumamoto, Japan</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>I-P-08</th>
<th>The role of RAGE and AGE on kidney failure in patients with familial amyloidotic polyneuropathy</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Noriko Matsunaga, Intissar Anan, Peter Rosenberg, Ryogi Nagai, Setkoh Hortuchi, Yukio Ando, Ole B Suhr</td>
</tr>
<tr>
<td></td>
<td>Kumamoto, Japan</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>I-P-09</th>
<th>Advanced glycation end products (AGE) and the receptor for AGE are present in familial amyloidotic polyneuropathy patients' gastrointestinal tract but do not induce NfkB activation</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Noriko Matsunaga, Intissar Anan, Peter Rosenberg, Yukio Ando, Ole B Suhr</td>
</tr>
<tr>
<td></td>
<td>Kumamoto, Japan</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>I-P-10</th>
<th>Identification of transthyretin variants by mass spectrometric peptide mapping</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Amareth Lim, Mark E. McComb, Tatiana Prokova, Lawreen H Connors, Martha Skinner, Catherine E Costello</td>
</tr>
<tr>
<td></td>
<td>Boston, USA</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>I-P-11</th>
<th>Studies on in vivo formed transthyretin amyloid fibrils</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Joakim Bergstrom, Charles Murphy, Alan Solomon, Per Westermark</td>
</tr>
<tr>
<td></td>
<td>Uppsala, Sweden</td>
</tr>
</tbody>
</table>
| I-P-12 | Characterization of TTR variants using intelligent data acquisition LC-MS/MS  
Catherine E Costello, Mark E McComb, Amareth Lim, Tatiana Prokoeva, Lawreen H. Connors, Martha Skinner  
Boston, USA |
|--------|-------------------------------------------------------------|
| I-P-13 | Sulfite and mutant transthyretin TTR-M119 protect amyloidogenic TTR-M30 against decay of tetramers into monomers  
Klaus Althaus, Pia Winter, Maria Joao M Saraiva, and Ole Suhr  
Giessen, Germany |
| I-P-14 | The novel highly destabilized A25T TTR variant rapidly misfolds, resulting in CNS amyloidosis - degradation of a highly amyloidogenic variant as a protective mechanism?  
Yoshiki Sekijima, Per Hammarström, Miyuki Matsumura, Yuko Shimizu, Makoto Iwata, Takahiko Tokuda, Shu-ichi Ikeda, Jeffery W Kelly  
La Jolla, USA |
| I-P-15 | Role of transthyretin in Alzheimer disease pathology  
Jeffrey D Benson, Barbara Klue-Reckerman, Shelia Little, Steven Paul, Masaki Tukao, Bernardino Ghezzi, Merrill D Benson  
Indiana, USA |
| I-P-16 | Amyloid associated proteins in Aβ amyloid in APPsw mice  
Mikio Shoji, Takeshi Kawarabayashi, Teisuro Murakami, Etsuro Matsubara, Isao Nagano, Yasuo Harigaya, Yoshinobu Hoshii, Hiroo Kawano, Tokuhiro Ishihara, Koji Abe  
Okayama, Japan |
| I-P-17 | Differences of serum proteome between amyloid positive and negative in TTR amyloid model mice  
Yutaka Takaoka, Mika Ohta, Hideki Matsuzaki, Naoya Hatano, Nobuko Sato, Yoshitake Satoaki, Ken-ichi Yamamura  
Moriori, Japan |
| II-P-18 | Amyloidotic amyotrophy in familial amyloidotic polyneuropathy  
Taro Yamashita, Yuko Ando, Masaaki Nakamura, Konen Obayashi, Katsuki Harada, Takahiro Tajiri, Yutaka Taniue, Mitsuharu Ueda, Mako Uchino  
Kumamoto, Japan |
| II-P-19 | Two cases with senile systemic transthyretin amyloidosis presenting as bilateral carpal tunnel syndrome  
Yo-ichi Takei, Takeshi Hattori, Takahiko Tokuda, Shu-ichi Ikeda  
Matsumoto, Japan |
| II-P-20 | Carpal tunnel syndrome associated with transthyretin amyloid deposition  
Tatsunori Murakami, Shinjiro Tabishima, Yoshitake Sanada  
Kurashiki, Japan |
| II-P-21 | Type I FAP (FAP TTR Met30) in Japan: early- versus late-onset form  
Haruki Koike, Ken-ichiro Misu, Shu-ichi Ikeda, Yukio Ando, Masamitsu Nakazato, Masahiko Yamamoto, Naoki Hattori, Gen Sobue  
Nagoya, Japan |
| II-P-22 | Aged onset of amyloidosis caused by transthyretin gene mutations  
Yukari Date, Masamitsu Nakazato  
Miyazaki, Japan |
| II-P-23 | Familial amyloidotic polyneuropathy (FAP) in Kyushu island  
Kaoru Hirakawa, Yukio Ando, Masaaki Nakamura, Shokuro Araki  
Kumamoto, Japan |
| II-P-24 | Characterization of the neurological involvement in hereditary amyloidosis  
TTR-related (HAA-TTR)  
Bologna, Italy |
| II-P-25 | Different prognosis in genetically defined HAA-TTR amyloidoses  
Bologna, Italy |

Wednesday September 25 (14:20 – 16:00)

| II-P-26 | Serine 6: more than a polymorphism  
Zeldenrust, SR, Jacobson, DR, Buscham J, Solomon, A, Murphy CL  
Babovic-Vuksanovic, D, Gertz, MA  
Rochester, U.S.A. |
| II-P-27 | First Spanish family with familial amyloid polyneuropathy associated to TTR  
Thr49 Ile mutation  
Saraiva MIM, Munar-Qués M, Madruga PD, Paul Moreira, Viader-Farré C  
Porto, Portugal |
| II-P-28 | A case of FAP ATTR Ser49Ile with spino-cerebellar atrophy (SCA) type 8  
Kanako Hata, Yukio Ando, Masaaki Nakamura, Hiroaki Okabe  
Kumamoto, Japan |
| II-P-29 | A new transthyretin mutation (Tyr78Phe) associated with peripheral neuropathy and carpal tunnel syndrome  
Nadine Magy, Juris J Liepniece, Helder Gil, Bernadette Kantelejo, Jean-Louis Dupond, Merril D Benson  
Indiana, U.S.A. |
| II-P-30 | Transthyretin Ser-44 mutation in a case with vitreous amyloidosis  
A Murakami, S Hasegawa, S Inauma, H Kowano, T Matsumoto, T Yamada  
Tokyo, Japan |
| II-P-31 | Biochemical characterization of Ile84Ser transthyretin vitreous amyloid  
Juris J Liepniece, Donald W Wilson, Merrill D Benson  
Indiana, U.S.A. |
| II-P-32 | Vitreous opacity is one of the most important initial symptoms in FAP  
Takahiro Kawaji, Eiko Ando, Akira Hira, Yukio Ando, Hidenobu Tanihara  
Kumamoto, Japan |
| II-P-33 | Phenotypic and genotypic heterogeneity in cardiac amyloidosis  
C Ravezzi, E Perugini, M Santi, C Magelli, O Leone, E Salvi, F Pastorelli, CA Tassinari, A Ferlini, E Zanagi, C Cellini, M Carro  
Bologna, Italy |
<table>
<thead>
<tr>
<th>Session</th>
<th>Title</th>
<th>Authors</th>
<th>Institutions</th>
</tr>
</thead>
<tbody>
<tr>
<td>II-P-34</td>
<td>A comparison of the echocardiographic features of familial amyloid polynuropathy (FAP) and primary (AL) amyloidosis</td>
<td>Jun Koyama, Shu-ichi Ikeda, Rodney H Falk</td>
<td>Matsumoto, Japan</td>
</tr>
<tr>
<td>II-P-35</td>
<td>Histopathologic findings in amyloid heart disease: comparison between AL and ATTR amyloidosis and genotype-phenotype correlations</td>
<td>O Leong, C Raperzi, E Perugini, M Santi, C Mogelli, F Sali, F Pastorelli, CA Tassiniari, A. Ferlini, E. Zamagni, C. Cellini, M. Cavo</td>
<td>Bologna, Italy</td>
</tr>
<tr>
<td>II-P-36</td>
<td>Transthyretin I122 cardiomyopathy in a clinic population of African Americans</td>
<td>T Prokaeva, LH Connors, A Lim, RH Falk, R Théberge, CE Costello, M Skinner</td>
<td>Boston, U.S.A.</td>
</tr>
<tr>
<td>II-P-37</td>
<td>Severe cardiac involvement in familial transthyretin type amyloid polynuropathy</td>
<td>Takeshi Hattori, Yo-ichi Takei, Jun Koyama, Shu-ichi Ikeda</td>
<td>Matsumoto, Japan</td>
</tr>
<tr>
<td>II-P-38</td>
<td>Late potentials in the ECG in patients with familial amyloidotic polynuropathy, Portuguese type</td>
<td>Rolf Horsten, Urban Wiklund, Bert Ove Olofsson, Ole B Suhr</td>
<td>Umeå, Sweden</td>
</tr>
<tr>
<td>II-P-39</td>
<td>Tc99m-DPD scintigraphy in transthyretin-type amyloidosis</td>
<td>Klaus Ahland, Max Puille, Reinhold P. Linke, Rtgobert Klett, Richard Bauer</td>
<td>Giessen, Germany</td>
</tr>
<tr>
<td>II-P-40</td>
<td>Analysis of myocardial sympathetic innervation in patients with cardiac amyloidosis using I-123 MIBG imaging</td>
<td>Minoru Hongo, Ryutchi Kai, Yoshikazu Yazaki, Osamu Kinoshita, Mafumi Owa</td>
<td>Matsumoto, Japan</td>
</tr>
<tr>
<td>II-P-41</td>
<td>Histopathological analysis of renal biopsies of FAP</td>
<td>Takashi Ehara, Hidekazu Shigematsu</td>
<td>Matsumoto, Japan</td>
</tr>
<tr>
<td>II-P-42</td>
<td>A new screening method for FAP</td>
<td>Hirokazu Furuya, Yukio Ando, Osamu Suzuki, Shogo Moriya, Jun-ichi Kira</td>
<td>Fukuioka, Japan</td>
</tr>
<tr>
<td>II-P-43</td>
<td>α1-microglobulin urinary excretion is a marker of early renal dysfunction in patients with familial amyloidotic polynuropathy</td>
<td>Neves FC, Conceição I, Matias J, Rodrigues HL, Carvalho M, Nunes, Prata MM</td>
<td>Lisbon, Portugal</td>
</tr>
<tr>
<td>II-P-44</td>
<td>Familial amyloidotic polynuropathy type I (Val30Met) – A risk factor for osteoporosis</td>
<td>1.Conceição I, Lac Miranda, R Gouveia, E Simões, M Parente, T Evangelista, M de Carvalho</td>
<td>Lisbon, Portugal</td>
</tr>
<tr>
<td>II-P-45</td>
<td>Physio-pathological examinations in transthyretin-related amyloidosis</td>
<td>Katsuki Haraoka, Yukio Ando, Masaaki Nakamura, Taro Yamashita, Kenen Ohayashi</td>
<td>Kumamoto, Japan</td>
</tr>
</tbody>
</table>
| II-P-46 | Contribution of wild-type transthyretin to peripheral nerve amyloid in a patient with Ala25Ser variant  
Masahide Yasaki, Juris J. Liepniece, John C. Kincade, Merrill D. Benson  
Indiana, U.S.A. |
| II-P-47 | A lysozyme variant Phe57Ile associated with hereditary renal amyloidosis  
Masahide Yasaki, Sandra A. Farrell, Merrill D. Benson  
Indiana, U.S.A. |
| II-P-48 | Apolipoprotein A-II amyloidosis with a new mutation (Stop 78 Arg)  
Masahide Yasaki, Juris J Liepniece, Barbara Klue-Beckerman, Mark S Barats,  
Arthur H Cohen, Merrill D Benson  
Indiana, U.S.A. |
| II-P-49 | Gelsolin-related familial amyloidosis, Finnish type in a Portuguese family  
– Clinical and neurophysiological studies  
I Conceição, ML Sales-Luís, M. de Carvalho, T. Evangelista, R. Fernandes, T  
Paunio, H Kangas, MJM Saravia  
Lisbon, Portugal |
| II-P-50 | Fast and simultaneous genotyping of TTR V30M and T119M using FRET probes and real-time PCR  
Paulo MP Costa, Paul L Moreira  
Porto, Portugal |
| II-P-51 | The threat of having a hereditary disease  
Elisabeth Jonsén, Ole Suhr  
Umeå, Sweden |
| II-P-52 | Importance of supporting mental problems in FAP patients  
Miyo Okajima, Yukio Ando, Masako Shitada  
Kumamoto, Japan |
| II-P-53 | Way of thinking of FAP patients and their families — Analysis based on the transaction of the patients’ association —  
Chieko Kukinaka, Masako Shitada, Yukio Ando  
Kumamoto, Japan |
| II-P-54 | Gene therapy with RNA/DNA chimera oligonucleotides in FAP  
Masaki Nakamura, Mitsuharu Ueda, Yukio Ando  
Kumamoto, Japan |
| II-P-55 | The antisense approach in AL amyloidosis: Identification of monoclonal immunoglobulin and inhibition of its production by antisense oligonucleotides in vitro and in vivo models  
Satoko Ohno, Mitsuru Yoshimoto, Sabo Honda, Sae Miyachi, Fumio Itoh, Kohzoh Imai  
Sapporo, Japan |

Friday September 27 (9:20 –10:30)

| III-P-56 | Ten year experience in orthotopic liver transplantation in AH-TTR amyloidoses  
Salvi F., Plasmati R., Pastorelli F., Tassinari C.A., Mascialchi M., Ferlini A.,  
Rapezzi C., Magelli C., Jovine E., Pinna A.D.  
Bologna, Italy |
| III-P-57 | Outcome of liver transplantation for FAP Met30 – Results of a ten-years experience with 143 patients at the University Hospitals of Coimbra  
Alexandre Linhares Fortado, Joaquim Silva Viana, Fernando José Oliveira, José Batista Geraldes, Emanuel Fortado, Aurélio Ferreira, Carlos Bento, Helena Vieira, Silvia Neves, Carlos Seco, Rui Perdigoto, José Ferrão, Luis Tomé, Oscar Moia  
Coimbra, Portugal |
| III-P-58 | Long-term follow-up of cardiac autonomic function after liver transplantation for familial amyloidotic polyneuropathy, Portuguese type  
Urban Wiklund, Rolf Hornsten, Bert Ove Olufsson and Ole B Suhr  
Umeå, Sweden |
| III-P-59 | Peripheral nerve function in patients with familial amyloidotic polyneuropathy after liver transplantation  
Hiroshi Morita, Sachio Kobayashi, Teruko Asawa, Yo-ichi Takei, Takao Hashimoto, Toshihiko Iegami, Yasuhiko Hashikura, Seiji Kawasaki, Shu-ichi Ikeda  
Matsusoto, Japan |
| III-P-60 | Long-term follow-up of liver transplanted familial amyloid polyneuropathy (Portuguese type) patients' survival  
Ole B Suhr, Bo-Goran Ericzon, Styrhjörn Friman  
Umeå, Sweden |
| III-P-61 | Outcome of gastric retention after liver transplantation for familial amyloidotic polyneuropathy, Portuguese type  
Ole B Suhr, Katrine Riklund Ahlström, Anders Rydh  
Umeå, Sweden |
| III-P-62 | Renal biopsy is useful to estimate the indication of liver transplantation in FAP patients  
Kenya Oguchi, Yo-ichi Takei, Takeshi Hattori, Shu-ichi Ikeda  
Matsusoto, Japan |
| III-P-63 | Pacemaker during liver transplantation for FAP Met30 – A 143 cases experience  
Joaquim Silva Viana, Alicia Romero, Helena Vieira, Silvia Neves, Carlos Bento, Carlos Seco, Rui Perdigoto, José Ferrão, Alexandre Linhares Fortado  
Coimbra, Portugal |
| III-P-64 | Cardiac conduction and rhythm disturbances after liver transplantation for familial amyloidotic polyneuropathy, Portuguese type  
Ole B Suhr, Rolf Hornsten, Bert Ove Olufsson, Urban Wiklund  
Umeå, Sweden |
| III-P-65 | Progression of cardiac disturbance after liver transplantation for familial amyloidosis  
S Dinamian, C Jun, I Moraru, C Sebag, D Le Guludec, M Slama  
Clamart, France |
| III-P-66 | Course of cardiac amyloidosis following liver transplantation (OLT) for familial amyloid polyneuropathy (FAP): The UK experience  
Arie J Stanton, Jayshree Joshi, Mark Monaghan, John O’Grady, Mohamed Rela, Nigel Heaton, Mark B Peys, Philip N Hawkins  
London, U.K. |
<table>
<thead>
<tr>
<th>III-P-67</th>
<th>Ocular involvement in patients with familial amyloidotic polyneuropathy (FAP) after liver transplantation in Japan</th>
</tr>
</thead>
<tbody>
<tr>
<td>Eiko Ando, Yukiko Ando, Katsuko Haraoka, Akira Kimura, Akira Hirata, Hiidenobu Tamihara</td>
<td></td>
</tr>
<tr>
<td>Kumamoto, Japan</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>III-P-68</th>
<th>Preoperative nutritional status and graft matching in liver transplantation for FAP: comparative study of full-size and technical-variant (reduced-size/split) grafts</th>
</tr>
</thead>
<tbody>
<tr>
<td>Taizan Urashashi, Stephen V. Lynch, Glenda A. Balderson, Jonathan W. Fawcett, Darryl HG Crawford, Akira Chikamoto, Mitsuyoshi Iwaya, Russell W. Strong</td>
<td></td>
</tr>
<tr>
<td>Brisbane, Australia</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>III-P-69</th>
<th>Comparison of sural nerve findings before and after liver transplantation in FAP patients</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yo-ichi Takei, Takeshi Hattori, Shu-ichi Ikeda</td>
<td></td>
</tr>
<tr>
<td>Matsumoto, Japan</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>III-P-70</th>
<th>Amyloid mass estimated before and after liver transplantation in TTR familial amyloid polyneuropathy. No evidence of regression in biopsies pf nine patients</th>
</tr>
</thead>
<tbody>
<tr>
<td>Reinhold P. Linke, Intissar Anan, Ole B. Suhr</td>
<td></td>
</tr>
<tr>
<td>Marisingfed, Germany</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>III-P-71</th>
<th>Combined heart and liver transplantation for transthyretin-related amyloidosis (ATTR)</th>
</tr>
</thead>
<tbody>
<tr>
<td>GApexella, F. Salvi, C Magelli, C Roppezi, E Perugini, M Santi, F Grigioni, F Pastorelli, CA Tassinari, A Cavallari</td>
<td></td>
</tr>
<tr>
<td>Bologna, Italy</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>III-P-72</th>
<th>Domino living donor liver transplantation in Shinshu University Hospital</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tachihiko Ikegami, Setji Kawasaki, Koichi Urata, Yoich Nakazawa, Yasuhiko Hashikura, Masaru Terada, Shinichi Miyagawa, Yo-ichi Takei, Shu-ichi Ikeda</td>
<td></td>
</tr>
<tr>
<td>Matsumoto, Japan</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>III-P-73</th>
<th>Domino liver transplantation using the whole liver shipped after living donor transplantation for familial amyloid polyneuropathy patient</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hajime Ohshiro, Katsuhiko Asonuma, Yukihiro Inomata, Koichi Tanaka</td>
<td></td>
</tr>
<tr>
<td>Kumamoto, Japan</td>
<td></td>
</tr>
</tbody>
</table>